These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 8205079

  • 1. Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors.
    Verma UN, Bagg A, Brown E, Mazumder A.
    Bone Marrow Transplant; 1994 Feb; 13(2):115-23. PubMed ID: 8205079
    [Abstract] [Full Text] [Related]

  • 2. Design and validation of a clinically applicable culture procedure for the generation of interleukin-2 activated natural killer cells in human bone marrow autografts.
    Klingemann HG, Deal H, Reid D, Eaves CJ.
    Exp Hematol; 1993 Aug; 21(9):1263-70. PubMed ID: 8330650
    [Abstract] [Full Text] [Related]

  • 3. Cytokine treatment of human bone marrow activates anti-leukaemia effector cells: monitoring of purging by polymerase chain reaction and DNA analysis.
    Dickinson AM, Middleton SL, Latham J, Dunn J, Thomas L, Proctor SJ.
    Leukemia; 1995 Mar; 9(3):444-9. PubMed ID: 7533866
    [Abstract] [Full Text] [Related]

  • 4. Preferential sequestration in vitro of BCR/ABL negative hematopoietic progenitor cells among cytokine nonresponsive CML marrow CD34+ cells.
    Veena P, Cornetta K, Davidson A, Agüero B, McMahel J, Traycoff CM, Srour EF.
    Bone Marrow Transplant; 1997 Jun; 19(12):1213-21. PubMed ID: 9208115
    [Abstract] [Full Text] [Related]

  • 5. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
    Wong EK, Eaves C, Klingemann HG.
    Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
    [Abstract] [Full Text] [Related]

  • 6. A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.
    Klingemann HG, Wong E, Maki G.
    Biol Blood Marrow Transplant; 1996 May; 2(2):68-75. PubMed ID: 9118301
    [Abstract] [Full Text] [Related]

  • 7. Culture of normal and leukemic bone marrow in interleukin-2: analysis of cell activation, cell proliferation, and cytokine production.
    Klingemann HG, Neerunjun J, Schwulera U, Ziltener HJ.
    Leukemia; 1993 Sep; 7(9):1389-93. PubMed ID: 8371589
    [Abstract] [Full Text] [Related]

  • 8. Preclinical studies for adoptive immunotherapy in bone marrow transplantation. Generation of anti-CD3 activated cytotoxic T cells from normal donors and autologous bone marrow transplant candidates.
    Ueda M, Joshi ID, Dan M, Uberti JP, Chou TH, Sensenbrenner LL, Lum LG.
    Transplantation; 1993 Aug; 56(2):351-6. PubMed ID: 8356589
    [Abstract] [Full Text] [Related]

  • 9. A novel approach to purging of leukemia by activation of bone marrow with interleukin 2.
    Charak BS, Malloy B, Agah R, Mazumder A.
    Bone Marrow Transplant; 1990 Sep; 6(3):193-8. PubMed ID: 2252959
    [Abstract] [Full Text] [Related]

  • 10. Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors.
    Verma UN, Areman E, Dickerson SA, Kotula PL, Sacher R, Mazumder A.
    Bone Marrow Transplant; 1995 Feb; 15(2):199-206. PubMed ID: 7773209
    [Abstract] [Full Text] [Related]

  • 11. Long-term culture of chronic myeloid leukemia (CML) bone marrow cells.
    Santucci MA, Zaccaria A, Testoni N, Russo D, Zuffa E, Baccarani M, Tura S.
    Haematologica; 1991 Feb; 76(5):357-62. PubMed ID: 1806437
    [Abstract] [Full Text] [Related]

  • 12. Regulatory activity of endogenous MIP-1 alpha in long-term cultures of human marrow.
    Cashman JD, Eaves AC, Wolpe S, Eaves CJ.
    Prog Clin Biol Res; 1994 Feb; 389():261-8. PubMed ID: 7700910
    [No Abstract] [Full Text] [Related]

  • 13. Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia.
    Scheffold C, Brandt K, Johnston V, Lefterova P, Degen B, Schöntube M, Huhn D, Neubauer A, Schmidt-Wolf IG.
    Bone Marrow Transplant; 1995 Jan; 15(1):33-9. PubMed ID: 7538001
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-12 (IL-12) alone or in synergistic combination with IL-2 for in vitro activation of human bone marrow: differential effects at different time points.
    Verma UN, Mazumder A.
    Bone Marrow Transplant; 1995 Sep; 16(3):365-72. PubMed ID: 8535308
    [Abstract] [Full Text] [Related]

  • 15. Behavior in vitro of long-term cultured bone marrow or blood cells from chronic myeloid leukemia: adhesion molecules and differentiation antigens as detected by immunocytochemistry.
    Pasternak G, Pasternak L.
    Folia Biol (Praha); 1994 Sep; 40(6):439-54. PubMed ID: 7589702
    [Abstract] [Full Text] [Related]

  • 16. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 17. Differential kinetics of primitive hematopoietic cells assayed in vitro and in vivo during serum-free suspension culture of CD34+ blood progenitor cells.
    Möbest D, Goan SR, Junghahn I, Winkler J, Fichtner I, Hermann M, Becker M, de Lima-Hahn E, Henschler R.
    Stem Cells; 1999 Aug; 17(3):152-61. PubMed ID: 10342558
    [Abstract] [Full Text] [Related]

  • 18. Long-term culture of canine marrow: cytogenetic evaluation of purging of lymphoma and leukemia.
    Carter RF, Kruth SA, Valli VE, Dubé ID.
    Exp Hematol; 1990 Oct; 18(9):995-1001. PubMed ID: 2397754
    [Abstract] [Full Text] [Related]

  • 19. [The effect of anti-bcr-abl hammerhead ribozyme on bone marrow purging].
    Wu Y, Chen YZ, Huang HF, Chen P, Lu LH.
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Sep; 35(9):859-63. PubMed ID: 12958661
    [Abstract] [Full Text] [Related]

  • 20. Eilatin: a novel marine alkaloid inhibits in vitro proliferation of progenitor cells in chronic myeloid leukemia patients.
    Einat M, Lishner M, Amiel A, Nagler A, Yarkorli S, Rudi A, Kashman Y, Markel D, Fabian I.
    Exp Hematol; 1995 Dec; 23(14):1439-44. PubMed ID: 8542929
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.